Marc Bonaca MD MPH

Many PAD patients fear a heart attack but have never heard of #acutelimbischemia #ALI. The risk is similar to MI and Stroke and the outcomes are poor. Do you talk to your #PAD patients about ALI? #peripheralarterydisease

The American Journal of Managed Care, Colorado Prevention Center, & the University of Colorado, present: Institute for Value-Based Medicine, Population Health Lipid Risk Management Forum & Dinner, Chaired by Dr. Marc Bonaca! More info/to register: event.ajmc.com/event/IVBMAugu…

Great to meet new colleagues & see old friends @CUAnschutz for final cardiology #Grand Rounds of 2023-24 #majesticWest #RockyMountainWild @cpcresearch #cardiometabolic @MarcBonaca (📸 credit) @kofi_larry #ConnieHess @StephenWaldoMD

What is #JACC about? Listen as Editor-in-Chief Dr. Harlan Krumholz details why JACC is focused on impact 💥 and ensuring the future of cardiovascular health around the globe 🌎 is better than the past. Watch ⬇️ & learn more here: bit.ly/3VTRAh2 @hmkyale

🌟 2023 Impact Factors are in! The #JACCJournals portfolio remains the strongest among the major cardiovascular portfolios of peer reviewed journals. All eligible JACC Journals ranked in the top 18. More: bit.ly/2OvgHq7 #Cardiology

Vascular medicine expert @MarcBonaca gave us his perspective on the new #PAD guidelines ⬇️#06B312A9FAFB4569ACFCD108061D736D" target="_blank" rel="nofollow noopener">healio.com/news/cardiolog…

Our analysis from VOYAGER-PAD trial published in @CircAHA. New data on Rivaroxaban plus Aspirin in PAD+CAD patients undergoing LER. Thanks to EC Members and Co-Authors! #VascularMedicine @MarcBonaca @cpcresearch @CUDeptMedicine @CUCardiology. ahajournals.org/doi/10.1161/CI…

A weekend well spent discussing plans for preventing and for improving outcomes for patients with CLTI with the top guns in this field @World_fvs @Vascular_India @VascularSVS @ESVSmembership @DGArmstrong @jmills1955 @RMotaganahalli @drvsbedi @RKTvascular

1/ Released today, the 2024 Peripheral Artery Disease Guideline was developed by AHA and @ACCIntouch in collaboration with and endorsed by: @AACVPR @APMA @abcardio1 @SCAI @SVM_tweets @for_svn @VascularSVS @SIRspecialists @VESurgery 📷 The process for multi-society involvement

We just wrapped our final press conference for #ACC24! ✅ A big thank you to discussants Dr. @MarcBonaca, Dr. @jennifer_rymer and @kim_guibone, DNP, for their excellent remarks to close out the press program.

You have found it! Your source for free CE/CME via Twitter! Each program provides 0.5h credit for #physicians, #pharmacists, and #nurses on topics of interest in the cardiometabolic space. Expert authors! See archived programs (and still earn credit) at cardiometabolic-ce.com.

Predicting amputation in PAD - Adding patient comorbidity / diabetes improves risk stratification - should WIFI be DM-WIFI? #ACC2024 #ACC24

Major adverse limb events higher in patients with below knee disease - results from the VOYAGER PAD Angiographic Core Lab #ACC2024 #ACC24

Vascular Year in Review #ACC24 #ACC2024 - exciting new studies including colchicine for AAA!

Next stop 🛑 in B309 is Kevin Rogers presenting - Risk of Adverse Events in Peripheral Artery Disease Patients with Below-Knee Disease: An Analysis from the VOYAGER-PAD Catheter-Based Angiographic Core Lab at 8:49 AM ET! 🚂🚃

Connie Hess shows new data from VOYAGER PAD on the efficacy and safety of DAPT after endovascular lower extremity revascularization! #ACC2024 #ACC24

@JJheart_doc @MidAmericaHeart @MkosiborodMD @MarcBonaca @JavedButler1 @RyanTedfordMD @robmentz @dranulala @noshreza @mvaduganathan @AlexMebazaa Next up, CONFIRMATION-HF.

@MidAmericaHeart is proud to announce we randomized first patient in REDEFINE-HF, an international, randomized, placebo-controlled, event-driven trial of finerenone for the treatment hospitalized heart failure patients with HFmrEF/HFpEF. classic.clinicaltrials.gov/ct2/show/NCT06…

Super excited about the multispecialty faculty (VS, IR, IC, VM) - all passionate about education! Whether you want to set yourself up for success in managing your vascular patients or simply win vascular jeopardy, we are ready for you! Travel stipend for 1st time attendees 😎

Great pleasure to present data from VOYAGER-PAD trial on Fragile patients at #AHA23. @AHAMeetings @PVDCouncil @cpcresearch @MarcBonaca

A scary map! #PADCollaborative Calling all of you to be a FORCE to fight against the amputation epidemic #AHA23 #PADCollaborative #CLTI #Amputationmap @PVDCouncil @AHAScience @AHAMeetings #structuralracism #ampute #PAD @hmpVDM @VMJ_SVM #SVM